N J McHugh1, P Owen, B Cox, J Dunphy, K Welsh. 1. Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath, Somerset BA1 1RL UK. neil.mchugh@rnhrd-tr.swest.nhs.uk
Abstract
OBJECTIVE: To conduct a case-control study to investigate whether there are independent tumour necrosis factor alpha (TNFalpha) or lymphotoxin alpha (LTalpha) haplotype associations with SLE or with any of the major serological subsets of SLE. METHODS: 157 patients with SLE were genotyped for HLA-DRB1, HLA-DQB1, TNFalpha, and LTalpha alleles by polymerase chain reaction and compared with 245 normal white controls. For TNFalpha, six single nucleotide polymorphisms (SNPs) at positions -1031, -863, -857, -308, -238, and +488 and for LTalpha three SNPs at positions +720, +365, and +249 were studied to assign six TNFalpha haplotypes (TNF1-6) and four LTalpha haplotypes (LTA1-4). All SLE patients had full serological profiles on serial samples. RESULTS: The most significant association with SLE overall was with HLA-DR3 (p<0.001; odds ratio (OR) = 2.5 (95% confidence interval, 1.6 to 3.8)) and the extended haplotype HLA-DQB1*0201;DRB1*0301;TNF2;LTA2 (p<0.001; OR = 2.3 (1.4 to 3.7)). Associations were strongest in the anti-La positive group (13%) of SLE patients (HLA-DR3, OR = 71 (9 to 539); HLA-DQB1*0201, OR = 35 (5 to 267); TNF2, OR = 10 (2.8 to 36), and LTA2, OR = 4.9 (1.1 to 21)). There was an increase in the HLA-DR2 associated extended haplotype (HLA-DQB1*0602;DRB1*1501;TNF1;LTA1) in patients with anti-Ro in the absence of anti-La (p<0.005; OR = 3.9 (1.5 to 10)). The HLA-DR7 extended haplotype (HLA-DQB1*0303;DRB1*0701/2;TNF5;LTA3) was decreased in SLE overall (p<0.02; OR = 0.2 (0.05 to 0.8)). CONCLUSIONS: The strongest association in this predominantly white population with SLE was between HLA-DR3 and anti-La, which seemed to account for any associations with TNFalpha alleles on an extended DR3 haplotype.
OBJECTIVE: To conduct a case-control study to investigate whether there are independent tumour necrosis factor alpha (TNFalpha) or lymphotoxin alpha (LTalpha) haplotype associations with SLE or with any of the major serological subsets of SLE. METHODS: 157 patients with SLE were genotyped for HLA-DRB1, HLA-DQB1, TNFalpha, and LTalpha alleles by polymerase chain reaction and compared with 245 normal white controls. For TNFalpha, six single nucleotide polymorphisms (SNPs) at positions -1031, -863, -857, -308, -238, and +488 and for LTalpha three SNPs at positions +720, +365, and +249 were studied to assign six TNFalpha haplotypes (TNF1-6) and four LTalpha haplotypes (LTA1-4). All SLEpatients had full serological profiles on serial samples. RESULTS: The most significant association with SLE overall was with HLA-DR3 (p<0.001; odds ratio (OR) = 2.5 (95% confidence interval, 1.6 to 3.8)) and the extended haplotype HLA-DQB1*0201;DRB1*0301;TNF2;LTA2 (p<0.001; OR = 2.3 (1.4 to 3.7)). Associations were strongest in the anti-La positive group (13%) of SLEpatients (HLA-DR3, OR = 71 (9 to 539); HLA-DQB1*0201, OR = 35 (5 to 267); TNF2, OR = 10 (2.8 to 36), and LTA2, OR = 4.9 (1.1 to 21)). There was an increase in the HLA-DR2 associated extended haplotype (HLA-DQB1*0602;DRB1*1501;TNF1;LTA1) in patients with anti-Ro in the absence of anti-La (p<0.005; OR = 3.9 (1.5 to 10)). The HLA-DR7 extended haplotype (HLA-DQB1*0303;DRB1*0701/2;TNF5;LTA3) was decreased in SLE overall (p<0.02; OR = 0.2 (0.05 to 0.8)). CONCLUSIONS: The strongest association in this predominantly white population with SLE was between HLA-DR3 and anti-La, which seemed to account for any associations with TNFalpha alleles on an extended DR3 haplotype.
Authors: M Rischmueller; S Lester; Z Chen; G Champion; R Van Den Berg; R Beer; T Coates; J McCluskey; T Gordon Journal: Clin Exp Immunol Date: 1998-02 Impact factor: 4.330
Authors: J Granados; G Vargas-Alarcón; C Drenkard; F Andrade; H Melín-Aldana; J Alcocer-Varela; D Alarcón-Segovia Journal: Lupus Date: 1997 Impact factor: 2.911
Authors: J McCluskey; A D Farris; C L Keech; A W Purcell; M Rischmueller; G Kinoshita; P Reynolds; T P Gordon Journal: Immunol Rev Date: 1998-08 Impact factor: 12.988
Authors: Yuan Zhang; Tae-Jin Kim; Joanna A Wroblewska; Vera Tesic; Vaibhav Upadhyay; Ralph R Weichselbaum; Alexei V Tumanov; Hong Tang; Xiaohuan Guo; Haidong Tang; Yang-Xin Fu Journal: Cell Mol Immunol Date: 2017-06-05 Impact factor: 11.530
Authors: Zhenhuan Zhao; Jiling Ren; Chao Dai; Carol C Kannapell; Hongyang Wang; Felicia Gaskin; Shu Man Fu Journal: Ann Rheum Dis Date: 2018-09-25 Impact factor: 19.103
Authors: Michelle M A Fernando; Christine R Stevens; Pardis C Sabeti; Emily C Walsh; Alasdair J M McWhinnie; Anila Shah; Todd Green; John D Rioux; Timothy J Vyse Journal: PLoS Genet Date: 2007-11 Impact factor: 5.917
Authors: Malarvili Selvaraja; Chun Lai Too; Lay Kim Tan; Bee Tee Koay; Maha Abdullah; Anim Md Shah; Masita Arip; Syafinaz Amin-Nordin Journal: Lupus Sci Med Date: 2022-02